Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer
作者： F Gay , L Collette , T Sahmoud , H Bleiberg , T Conroy
DOI: 10.1016/S0959-8049(97)00088-9
关键词:
摘要: Patients with measurable or evaluable locally advanced metastatic squamous cell carcinoma of the oesophagus were treated cisplatin (CDDP), 100 mg/m2, combined 5-fluorouracil (5-FU) at a dose 1000 mg/m2 as continuous infusion from days 1-5 (Arm A) CDDP alone B). Cycles repeated every 3 weeks. 92 patients randomised centrally, 88 eligible. The response rate was 35% (95% CI (confidence interval), 20-54%) in Arm A and 19% CI, 8-35%) B. One complete observed each arm. median duration survival 33 weeks 28 for B, respectively. Haematological non-haematological toxicities more frequent severe A. most prominent grade 4 aplasia septicaemia (2), meningeal haemorrhage (1), cerebrovascular accident (3) ischaemia lower limbs (1) all occurring Overall, seven treatment-related deaths (16%) A, none side-effects induced by combination suggest that, currently, no standard chemotherapy can be recommended oesophageal cancer.
ulb.ac.be
elsevier.com
sci-hub.se 参考文章(19)
Ajani Ja, Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Seminars in Oncology. ,vol. 21, pp. 474- 482 ,(1994)
Robert E. Wittes, Manual of oncologic therapeutics Lippincott. ,(1991)
D. G. Pfister, D. Bajorin, R. Motzer, H. Scher, C. Louison, L. Harrison, J. Shah, E. Strong, G. Bosl, Cisplatin, fluorouracil, and leucovorin : increased toxicity without improved response in squamous cell head and neck cancer Archives of Otolaryngology-head & Neck Surgery. ,vol. 120, pp. 89- 95 ,(1994) , 10.1001/ARCHOTOL.1994.01880250077011
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Thomas J. Lynch, Frederick Kass, Anthony D. Elias, Arthur Skarin, Emil Frei Iii, Leslie A. Kalish, Gary Strauss, Lawrence N. Shulman, David J. Sugarbaker, Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer Cancer. ,vol. 71, pp. 2953- 2957 ,(1993) , 10.1002/1097-0142(19930515)71:10<2953::AID-CNCR2820711011>3.0.CO;2-J
Stuart J. Pocock, Richard Simon, Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial Biometrics. ,vol. 31, pp. 103- 115 ,(1975) , 10.2307/2529712
O Atiq, Therapy of upper gastrointestinal tract cancers. Current Problems in Cancer. ,vol. 15, pp. 239- 294 ,(1991) , 10.1016/0147-0272(91)90018-6
Alain Roussel, Harry Bleiberg, Otilia Dalesio, JH Jacob, Pierre Haegele, GM Jung, Bernard Paillot, JF Heintz, Marc Gignoux, S Nasca, A Namer, Marc Buyse, Nicole Duez, EORTC Gastrointestinal Tract Cancer Cooperative Group, Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: Final results of a controlled clinical trial International Journal of Radiation Oncology Biology Physics. ,vol. 16, pp. 67- 72 ,(1989) , 10.1016/0360-3016(89)90011-4
Timothy Kuzel, Ben Esparaz, David Green, Merrill Kies, Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin Cancer. ,vol. 65, pp. 885- 889 ,(1990) , 10.1002/1097-0142(19900215)65:4<885::AID-CNCR2820650410>3.0.CO;2-H
Richard L. Edwards, Melissa Klaus, Eileen Matthews, Cheryl McCullen, Robert D. Bona, Frederick R. Rickles, Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels The American Journal of Medicine. ,vol. 89, pp. 25- 28 ,(1990) , 10.1016/0002-9343(90)90093-S